Dr. Hartmut Ehrlich, CEO, Abivax  gives an update of the French biotech's phase-2b clinical trial drug candidate ABX464 which has shown impressive results.  Dr. Ehrlich discusses how this revolutionary small molecule for oral administration has shown strong anti-inflammatory effects to solve the unmet needs of patients with inflammatory conditions like ulcerative colitis, Crohn's disease, and arthritis by using the body's own immune system to fight the diseases.

@abivax #abivax  #inflammation #IBD #rheum

Abivax.com

Download the transcript here